The Role of Circulating Biomarkers in Lung Cancer.

Herath, S; Sadeghi Rad, H; Radfar, P; Ladwa, R; Warkiani, M; O'Byrne, K; Kulasinghe, A

The Role of Circulating Biomarkers in Lung Cancer.

Herath, S Sadeghi Rad, H Radfar, P Ladwa, R Warkiani, M O'Byrne, K Kulasinghe, A

Permalink

Publisher:: Frontiers
Publication Type:: Journal Article
Citation:: Front Oncol, 2021, 11, pp. 801269
Issue Date:: 2021

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.76 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Herath, S
dc.contributor.author	Sadeghi Rad, H
dc.contributor.author	Radfar, P
dc.contributor.author	Ladwa, R
dc.contributor.author	Warkiani, M
dc.contributor.author	O'Byrne, K
dc.contributor.author	Kulasinghe, A
dc.date.accessioned	2023-06-30T01:51:38Z
dc.date.available	2021-12-21
dc.date.available	2023-06-30T01:51:38Z
dc.date.issued	2021
dc.identifier.citation	Front Oncol, 2021, 11, pp. 801269
dc.identifier.issn	2234-943X
dc.identifier.issn	2234-943X
dc.identifier.uri	http://hdl.handle.net/10453/171021
dc.description.abstract	Lung cancer is the leading cause of cancer morbidity and mortality worldwide and early diagnosis is crucial for the management and treatment of this disease. Non-invasive means of determining tumour information is an appealing diagnostic approach for lung cancers as often accessing and removing tumour tissue can be a limiting factor. In recent years, liquid biopsies have been developed to explore potential circulating tumour biomarkers which are considered reliable surrogates for understanding tumour biology in a non-invasive manner. Most common components assessed in liquid biopsy include circulating tumour cells (CTCs), cell-free DNA (cfDNA), circulating tumour DNA (ctDNA), microRNA and exosomes. This review explores the clinical use of circulating tumour biomarkers found in liquid biopsy for screening, early diagnosis and prognostication of lung cancer patients.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	Frontiers
dc.relation.ispartof	Front Oncol
dc.relation.isbasedon	10.3389/fonc.2021.801269
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.title	The Role of Circulating Biomarkers in Lung Cancer.
dc.type	Journal Article
utslib.citation.volume	11
utslib.location.activity	Switzerland
utslib.for	1112 Oncology and Carcinogenesis
utslib.copyright.status	open_access	*
dc.date.updated	2023-06-30T01:51:33Z
pubs.publication-status	Published online
pubs.volume	11

Abstract:

Lung cancer is the leading cause of cancer morbidity and mortality worldwide and early diagnosis is crucial for the management and treatment of this disease. Non-invasive means of determining tumour information is an appealing diagnostic approach for lung cancers as often accessing and removing tumour tissue can be a limiting factor. In recent years, liquid biopsies have been developed to explore potential circulating tumour biomarkers which are considered reliable surrogates for understanding tumour biology in a non-invasive manner. Most common components assessed in liquid biopsy include circulating tumour cells (CTCs), cell-free DNA (cfDNA), circulating tumour DNA (ctDNA), microRNA and exosomes. This review explores the clinical use of circulating tumour biomarkers found in liquid biopsy for screening, early diagnosis and prognostication of lung cancer patients.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/171021